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Background. Highly active antiretroviral therapy (HAART) has led to a dramatic decrease in AIDS-related mor-
bidity and mortality through sustained suppression of human immunodeficiency virus (HIV) replication and recon-
stitution of the immune response. Settings like China that experienced rapid HAART rollout and relatively limited
drug selection face considerable challenges in controlling HIV drug resistance (DR).
Methods. We conducted a systematic review and meta-analysis to describe trends in emergent HIV DR to first-
line HAART among Chinese HIV-infected patients, as reflected in the point prevalence of HIV DR at key points and
fixed intervals after treatment initiation, using data from cohort studies and cross-sectional studies respectively.
Results. Pooled prevalence of HIV DR from longitudinal cohorts studies was 10.79% (95% confidence interval
[CI], 5.85%–19.07%) after 12 months of HAART and 80.58% (95% CI, 76.6%–84.02%) after 72 months of HAART.
The HIV DR prevalence from cross-sectional studies was measured in treatment intervals; during the 0–12-month
HAART treatment interval, the pooled prevalence of HIV DR was 11.1% (95% CI, 7.49%–16.14%), which increased
to 22.92% at 61–72 months (95% CI, 9.45%–45.86%). Stratified analyses showed that patients receiving a didanosine-
based regimen had higher HIV DR prevalence than those not taking didanosine (15.82% vs 4.97%). Patients infected
through former plasma donation and those receiving AIDS treatment at village clinics had higher HIV DR preva-
lence than those infected through sexual transmission or treated at a county-level hospital.
Conclusions. Our findings indicate higher prevalence of HIV DR for patients with longer cumulative HAART
exposure, highlighting important subgroups for future HIV DR surveillance and control.
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Highly active antiretroviral therapy (HAART) has led
to a dramatic decrease in AIDS-related morbidity and
mortality [1,2] through sustained suppression of human
immunodeficiency virus (HIV) replication [3] and re-
constitution of the immune response [4]. However, the
eventual development of HIV drug resistance (DR) over
time is largely inevitable at the population level, and
HIV DR is one of the strongest predictors of treatment
failure [5, 6]. It can render existing therapies ineffective
[7–9], increasing the risk of viral rebound and opportu-
nistic infections. Second-line drugs provide alternative
therapeutic options to suppress resistant strains, but
their high cost and limited availability in some areas
make them a less viable option. As HIV DR prevalence
increases at the population level, the secondary trans-
mission of transmitted DR is also a major public health
concern [10]. A better understanding of long-term HIV
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DR rates and emergence of drug-resistant mutations after
HAART initiation will be crucial to the effective therapeutic
and preventive use of HAART.
China’s National Free Antiretroviral Treatment Program
(NFATP) is now a decade old [11], having begun as a pilot
program with just 100 enrollees in a rural region where most
patients were infected through former plasma donation in the
early 1990s [11, 12]. The program today is notable in terms of
both scale and impact. As of 31 December 2009, a cumulative
total of 82 540 patients received HAART through the program,
during which time the HIV/AIDS-related mortality rate fell
from 39.3 to 14.2 deaths per 100 person-years [13].
Owing to its early rapid scale-up, as well as evolving recom-
mendations for treatment eligibility—in 2008 China’s HAART
initiation threshold increased from 200 to 350 CD4 cells/µL
[14]—expansion of HAART access in China outpaced program
development in the early stages. Routine laboratory screening is
only available at a small portion of the >3700 HAART delivery
sites across the county; between 2005 and 2008, only 30% of
patients had received ≥1 viral load test a year [15]. Specialized
training in AIDS care for local providers is also limited, and in
rural areas many AIDS care physicians lack a formal medical
education [16]. These factors, along with the limited drug regi-
men choice in the early years of the program, have all contrib-
uted to the emergence of HIV DR in the Chinese HAART
population. Observational studies have shown that the pre-
valence of drug-resistant strains among treated HIV/AIDS pa-
tients in China ranges from 2.38% to 54.67% [17,18] after 1 year
of HAART. However, it is difficult to draw broader conclusions
owing to the heterogeneity of study populations and sampling
methods. Because few studies have traced trends of HIV DR
emergence during longer durations of HAART exposure, the
objective of this investigation was to conduct a systematic review
and meta-analysis and generate pooled estimates of the emerg-
ing trends of HIV DR after first-line HAART initiation in
Chinese patients with HIV/AIDS.
METHODS
Search Strategy and Data Extraction
We conducted a literature search using the PubMed/Medline
database, as well as Chinese language databases, including the
China National Knowledge Infrastructure, the Chinese Biomed-
ical Literature Database, and Wanfang, from inception to 28
February 2014, using the following search string: (HIV OR
human immunodeficiency virus OR AIDS OR acquired immu-
nodeficiency syndrome) AND (drug resistance OR drug resis-
tant) AND China. Articles published in English or Chinese
were considered for inclusion in this analysis.
Two independent reviewers (H. L. and Y. S.) determined
study eligibility, with a third reviewer (N. W.) deciding on
cases in which the opinions of the 2 main reviewers diverged.
Only studies with explicitly reported HIV DR prevalence data
were considered, after which the following inclusion criteria
were used to determine inclusion in the final analysis: (1)
adult patient population (>18 years of age); (2) treatment-
naive patient at baseline; (3) treatment with first-line HAART
regimen, consisting of 2 nucleoside reverse-transcriptase inhib-
itors and 1 nonnucleoside reverse-transcriptase inhibitor; (4)
AIDS care received through the NFATP (as opposed to private
care sought by patients); (5) available information on genotypic
HIV DR data, determined by the Stanford HIV Drug Resistance
Database Program (http://hivdb.standford.edu). If multiple arti-
cles on the same study were published, the one providing more
complete information and/or larger sample size was chosen.
Two reviewers (H. L. and L. Z.) independently extracted
study data, including author names, year of publication, study
type, study period, sample size, demographic information, in-
fection route, type of AIDS healthcare setting, initial HAART
regimen, and prevalence of patients with genotypic HIV DR
mutation(s). All HIV DR mutations that conferred low, inter-
mediate or high-level resistance are included [19].
Statistical Analyses
When follow-up data were available, pooled HIV DR prevalence
was estimated at various durations of HAART exposure by
identifying common milestones or time intervals used by all
studies. For cohort studies cumulative HIV DR prevalence esti-
mates were calculated at 12, 24, 36, 48, 60, and 72 months since
HAART initiation, and for cross-sectional studies estimates
were calculated at the following time intervals after HAART ini-
tiation: 0–12, 13–24, 25–36, 37–48, 49–60, and 61–72 months.
Separate methods were used to calculate HIV DR prevalence
for cohort studies and cross-sectional studies. For the former,
the denominator included all patients enrolled at baseline,
and the numerator represented the number found to be HIV
drug resistant at each of the above-mentioned milestones after
HAART initiation. Patients included in the numerator for a
given point prevalence were carried forward in the numerator
for all subsequent intervals. Patients who were lost to follow-
up at any point without a recorded HIV DR event were exclud-
ed from the calculation entirely. For cross-sectional studies,
patients were stratified into the aforementioned time intervals
that corresponded to their duration of HAART exposure. The
HIV DR prevalence was then calculated using the number of
patients in each treatment interval in the denominator and
the number who tested positive for HIV DR in the numerator.
Statistical heterogeneity was evaluated using the I2 test [20]
with a cutoff of I2 > 50% to represent moderate to substantial
heterogeneity, in which case random-effects models were used
to pooled the summary estimates. In cases with strong evidence
of heterogeneity, the HIV DR prevalence data were calculated
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for key subgroups, such as treatment regimen, original HIV
transmission route, and type of healthcare facility where
patients receive routine HIV/AIDS care. R software [21] and
SAS software (version 9.3; SAS Institute) were used for all stat-
istical analyses.
RESULTS
Study Selection and Characteristic
The search strategy yielded a total of 5095 abstracts (439 in
PubMed, 2070 in Wanfang, 1128 in the Chinese Biomedical
Literature Database, and 1458 in the China National Knowledge
Infrastructure). After removing duplicate articles, 2128 unique
studies were screened by title and abstract. Of these, 86 were re-
viewed in full text to determine eligibility based on the inclusion
criteria described above, yielding a final count of 25 articles in-
cluded in the final analysis (Supplementary Figure 1). Most ar-
ticles were excluded owing to lack of information on treatment
duration, HIV DR prevalence, or details on type of treatment
regimen. Longitudinal data on total of 2908 cohort study parti-
cipants and cross-sectional data from 6553 patients were ab-
stracted from the 12 cohort and 13 cross-sectional studies,
respectively. Most of the study sites were located in rural prov-
inces (Henan, Anhui, and Yunnan), and the most commonly
used nucleoside reverse-transcriptase inhibitors before 2005
were zidovudine and didanosine (ddI), which was largely re-
placed by lamivudine, and the most commonly used nonnu-
cleoside reverse-transcriptase inhibitors was nevirapine.
Cohort studies provided data on HIV DR at follow-up as long
as 72 months, but all data for HIV DR prevalence beyond 36
Table 1. Study Characteristics








Wang et al (2007) [22] Cohort Henan AZT + ddI + NVP 24 mo 107 NR
Huang (2008) [23] Cohort Anhui d4T + ddI + NVP 24 mo 90 NR
Li et al (2008) [24] Cohort 14 Clinical Centers AZT/d4T + ddI/3TC +NVP 12 mo 198 14
Zhang et al (2008) [25] Cohort Henan AZT/d4T + ddI/3TC +NVP 36 mo 88 NR
Ruan et al (2010) [26] Cohort Hunan, Henan, Anhui AZT/d4T + ddI/3TC +NVP/EFV 12 mo 341 76
Chen et al (2011) [27] Cohort Guangzhou AZT/d4T + ddI/3TC +NVP/EFV 24 mo 74 6
Cao et al (2011) [28] Cohort Henan AZT/d4T + 3TC +NVP/EFV 12 mo 105 3
Li et al (2011) [18] Cohort Henan AZT + ddI + NVP 72 mo 75 NR
Wang et al (2011) [29] Cohort Yunnan, Guangxi, Xinjiang AZT/d4T + 3TC +NVP 12 mo 435 84
Wang (2012) [30] Cohort 12 centers AZT/d4T + 3TC +NVP 12 mo 517 36
Liao et al (2013) [31] Cohort Henan and Anhui AZT/d4T + ddI + NVP 72 mo 365 NR
Wang et al (2014) [32] Cohort 8 cities TDF/AZT/d4T + 3TC +NVP/EFV 12 mo 513 65
Zhang et al (2008) [33] Cross-sectional 7 provinces AZT/d4T + ddI/3TC +NVP/EFV 2005 113 . . .
Yao (2009) [34] Cross-sectional Yunnan AZT/d4T + ddI/3TC +NVP/EFV 2008–2009 569 . . .
Yuan et al (2011) [35] Cross-sectional Henan AZT/d4T + ddI/3TC +NVP/EFV 2008–2009 299 . . .
Zheng et al (2011) [36] Cross-sectional Zhejiang AZT/d4T + ddI/3TC +NVP/EFV 2009 274 . . .
Zheng (2011) [37] Cross-sectional Henan AZT/d4T + ddI/3TC +NVP/EFV 2008–2009 105 . . .
Cui et al (2012) [38] Cross-sectional Henan AZT/d4T + ddI/3TC +NVP/EFV 2010 164 . . .
Qin et al (2012) [39] Cross-sectional Hunan AZT/d4T + ddI/3TC +NVP/EFV 2009 211 . . .
Sun et al (2012) [40] Cross-sectional Shandong 2 NRTIs + 1 NNRTI 2011 502 . . .
Xiao et al (2012) [41] Cross-sectional Jiangsu AZT/d4T + 3TC +NVP/EFV 2010 588 . . .
Yuan et al (2012) [42] Cross-sectional Henan AZT/d4T + ddI/3TC +NVP/EFV 2009 450 . . .
Cui et al (2013) [43] Cross-sectional Henan AZT/d4T + ddI/3TC +NVP Unavailable 120 . . .
Zhao et al (2013) [44] Cross-sectional 8 provinces AZT/d4T + ddI/3TC +NVP/EFV 2010 631 . . .
Xing et al (2013) [45] Cross-sectional 31 provinces AZT/d4T + ddI/4TC +NVP/EFV 2004–2006 2527 . . .
Abbreviations: 3TC, lamivudine; AZT, zidovudine; d4T, stavudine; ddI, didanosine; EFV, efavirenz; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NR, not
reported; NRTI, nucleoside reverse-transcriptase inhibitor; NVP, nevirapine; TDF, tenofovir.
a Duration of follow-up for cohort studies.
b Number of patients enrolled at baseline of cohort studies or recruited into cross-sectional studies.
c Number of patients lost to follow-up without any human immunodeficiency virus drug resistance test results in cohort studies.
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Figure 1. Pooled cumulative human immunodeficiency virus (HIV) drug resistance (DR) prevalence at each key point after highly active antiretroviral
therapy (HAART) initiation (data from cohort studies).
1498 • CID 2014:59 (15 November) • HIV/AIDS
Figure 2. Pooled human immunodeficiency virus (HIV) drug resistance (DR) prevalence at each treatment interval since highly active antiretroviral therapy
(HAART) initiation (data from cross-sectional studies).
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months came from 2 longitudinal studies set in Henan prov-
ince. Two cross-sectional studies provided HIV DR prevalence
data beyond 60 months, informed by data from studies set in
Henan and Jiangsu provinces (Table 1).
HIV DR Prevalence
We calculated pooled estimates of cumulative prevalence of
HIV DR after HAART initiation separately for cohort studies
and cross-sectional studies, respectively. Data from cohort stud-
ies (Figure 1) showed that the pooled HIV DR prevalence was
10.79% (95% confidence interval [CI], 5.85%–19.07%) at 12
months after HAART initiation, and at 72 months after initia-
tion, this same estimate was 80.58% (95% CI, 76.6%–84.02%).
The pooled HIV DR for the 0–12-month interval calculated
from cross-sectional studies (11.1%, 95% CI, 7.49%–16.14%)
was similar to that for cohort studies (10.79%, 95% CI,
5.85%–19.07%); however, estimates from the 2 study types
began to diverge after 13 months of HAART (13.72% at 13–
24 months for cross-sectional studies and 32.87% at 24 months
for cohort studies) (Figure 2).
Subgroup Analysis
We conducted subgroup analyses for cohort studies according
to type of HAART regimen (with or without ddI), HIV trans-
mission route, and type of primary healthcare facility (village
clinic vs public hospital) where patients received AIDS care. Be-
cause no cohort study in this analysis in which any patients re-
ceived ddI-based regimens exceeded 12 months of follow-up,
we were able to stratify HIV DR data only by treatment regimen
at 12 months of HAART. Patients treated with a regimen con-
taining ddI had much higher HIV DR rates than those with reg-
imens without ddI (15.82% vs 4.97%, Supplementary Figure 2).
When the HIV DR prevalence data were divided into groups by
patients’ infection route and treated agency, the patients who
were infected through former plasma donation had higher
HIV DR prevalence than those infected through sexual contact
(Figure 3A), and the HIV DR prevalence was also higher among
patients treated at village clinic or township hospitals than
among those treated at county or city hospitals (Figure 3B).
DISCUSSION
China’s NFATP was initially piloted in the former plasma
donor population in the early 2000s [11, 12], when patients
and healthcare providers had limited understanding of clinical
management of AIDS and treatment optimization. In that time,
patients were more likely to be treated at village clinic or town-
ship hospital with regimens containing ddI, an antiviral agent
that has been predictive of virologic failure in past analyses
[24]. By 2005, however, lamivudine had largely replaced ddI
in NFATP-subsidized regimens [45], and <20% of HIV/AIDS
patients were being treated at village clinics as opposed to coun-
ty hospitals by 2013 (data not published).
Results of our analysis showed that the cumulative HIV DR
prevalence rates increased with longer duration of HAART ex-
posure. The 12-month pooled estimates of HIV DR—10.79%
from cohort and 11.1% from cross-sectional studies—are higher
than rates reported by other meta-analyses (2.35%) [10]. One
possible explanation is that most Chinese patients who started
HAART at the early rollout phase (2003–2005) were more likely
to be exposed to a ddI-based regimen, which would lead to a
higher HIV DR prevalence. Although the pooled prevalence
of HIV DR after 72 months of HAART from cohort studies
was as high as 80.58%, the fact that only 2 studies, both from
Henan, provided the data for that subgroup analysis warns us
Figure 3. Emergence trends of human immunodeficiency virus (HIV) drug
resistance (DR) after highly active antiretroviral therapy (HAART) initiation
stratified by infection route (A) and treatment agency (B), based on data
from cohort studies. Each bubble represents a study, and the size of the
bubble figure corresponds to the study sample size; trend lines represent
predicted prevalence with 95% confidence intervals. Abbreviation: ART,
antiretroviral therapy.
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to interpret the rate with some caution. As a rural area, Henan
patients have little adherence support and may have been more
likely to have ddI-based regimens.
The pooled estimates of HIV DR prevalence at each treat-
ment interval from cross-sectional were lower than correspond-
ing estimates from cohort studies, probably for some of the
following reasons. First, by design, cross-sectional studies are
more vulnerable to selection bias because only patients with
prevalent HAART exposure who remain HIV DR negative
(the “survivors”) are eligible for inclusion in the study. It is
therefore likely that patients with a higher baseline risk of
HIV DR—whether from poorer treatment adherence or for
other reasons—are systematically excluded from inclusion in
these studies. Second, because we were calculating cumulative
prevalence of HIV DR, we carried forward all HIV DR–positive
cases for subsequent intervals. Finally, the HIV DR prevalence
data used to calculate pooled HIV DR prevalence after 36
months of HAART most likely reflect treatment outcomes in
patients in resource-poor areas of rural China, where treatment
adherence support is scarce and exposure to more toxic antivi-
rals (eg, ddI) is more common, both of which conditions could
lead to a higher HIV DR prevalence.
Subgroup analysis results showed that patients infected
through former plasma donation had the highest rates of HIV
DR. This is probably because the NFATP was initially piloted
in this population made up of mostly poor famers with limited
education and low health literacy. The stratified analysis also
showed that patients receiving HAART at village- or town-level
clinics had higher HIV DR rates than those treated at county hos-
pitals, a finding corroborated by the fact that most former plasma
donors seek medical care at village- or town-level clinics. Re-
source limitations and undertrained staff at these community-
based healthcare settings present major challenges for the preven-
tion of HIV DR in their patient populations.
Our study had several limitations. First, most subjects includ-
ed in this analysis were originally infected through plasma don-
ation, limiting the generalizability of results since China’s
epidemic has shifted to a sexually driven one [46], and most
new patients with HIV/AIDS bear little resemblance to former
plasma donors; they are younger, have more diverse risk behav-
iors, and have varied access to healthcare. Second, the HIV DR
testing is generally reserved for patients with a detectable viral
load (≥1000 copies/mL), leading to possible mismeasurement
of HIV DR. The high correlation between HIV DR virus and
higher viral load suggest that this issue was probably not a
source of major bias.
Observational data and modeling exercises have suggested
that other regions of the world with longer HIV treatment
histories are experiencing a rise in the incidence of acquired
HIV DR [47, 48]. The rapid scale-up of China’s HAART
program has hinged on leveraging existing community-based
infrastructures, which provided rapid delivery of program
drugs but may have contributed to an inflated rate of popula-
tion-level HIV DR [16]. Although the overall pooled estimates
of HIV DR in this analysis are by no means low, China’s HIV
DR problem does not seem more serious than in other develop-
ing country settings. As China continues to build healthcare
infrastructure, routine virologic monitoring and adherence sup-
port will be critical for controlling the emergence of HIV DR.
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